Skip to Content
EndocrinesEndocrines
  • Article
  • Open Access

2 September 2026

12 Pages

The Behavioral Immune System in Gender Transition: A Prospective Analysis of Associations Between Sex Steroids and Disgust Sensitivity During GAHT

,
,
,
,
,
,
,
and
1
Department of Experimental and Clinical Medicine, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, Italy
2
Department of Economic, Psychological, Communication, Education and Sport Sciences, Nicolò Cusano University, 00166 Rome, Italy
3
Endocrinology Unit, Renato Dulbecco University Hospital, 88100 Catanzaro, Italy
*
Author to whom correspondence should be addressed.

Abstract

Background/Objectives: Experimental and observational studies suggest that sex steroids may modulate disease-avoidance mechanisms and disgust-related responses, but longitudinal evidence in transgender individuals undergoing gender-affirming hormone therapy (GAHT) remains limited. This study investigated whether endocrine changes occurring during the first four months of GAHT were associated with changes in disgust sensitivity, body odor disgust, and perceived vulnerability to disease. Methods: A prospective observational study was conducted in 25 transgender adults (12 transmasculine [FtM] and 13 transfeminine [MtF]) evaluated before initiating GAHT (T0) and after four months of treatment (T1). Participants completed the Three Domains of Disgust Scale (TDDS), the Body Odor Disgust Scale (BODS), and the Perceived Vulnerability to Disease Scale (PVD). Serum testosterone and estradiol concentrations were measured at both time points. Within-group changes were assessed using Wilcoxon signed-rank tests, and associations between hormonal and psychometric changes were explored using Spearman correlations. Results: Among FtM participants, PVD increased significantly following treatment (p = 0.039), whereas no significant changes were observed in pathogen disgust, sexual disgust, moral disgust, or body odor disgust. Greater increases in testosterone were associated with greater reductions in moral disgust (ρ = −0.671, p < 0.05). Among MtF participants, pathogen disgust increased significantly after four months of GAHT (p = 0.015). Greater increases in estradiol were associated with higher moral disgust (ρ = 0.587, p < 0.05) and lower perceived vulnerability to disease (ρ = −0.748, p < 0.01). In addition, testosterone changes were positively associated with changes in sexual disgust (ρ = 0.570, p < 0.05). Conclusions: In this small exploratory cohort, changes in circulating sex steroids during the first four months of GAHT were statistically associated with changes in selected dimensions of disgust sensitivity and perceived vulnerability to disease. The findings are hypothesis-generating and require confirmation in adequately powered longitudinal studies.

1. Introduction

Sex steroids exert profound effects on a wide range of physiological, cognitive, affective, and social processes. Beyond their well-established role in reproductive function and sexual differentiation, testosterone (T) and estradiol (E2) influence emotional regulation, social cognition, risk perception, and behavioral responses to environmental stimuli [1,2]. Increasing evidence suggests that endocrine fluctuations may also modulate mechanisms involved in disease avoidance and pathogen detection, highlighting a potential interaction between hormonal regulation and behavioral defense systems [3,4].
One of the psychological systems implicated in disease avoidance is the behavioral immune system (BIS), a collection of cognitive, emotional, and behavioral mechanisms that evolved to identify and avoid potential sources of infection before pathogen exposure occurs [5,6,7]. Disgust represents a central component of this system and promotes avoidance of contamination-related stimuli.
Contemporary models conceptualize disgust as a multidimensional construct comprising at least three functional domains: pathogen disgust, which facilitates avoidance of infectious threats; sexual disgust, which may reduce exposure to reproductive and sexually transmitted risks; and moral disgust, which contributes to the regulation of social behavior and norm violations [8].
Several lines of evidence suggest that disgust-related processes may be sensitive to hormonal influences. Studies conducted during pregnancy and across periods of endogenous hormonal fluctuation have reported associations between steroid hormone levels and disease-avoidance responses, supporting the hypothesis that endocrine factors contribute to the regulation of behavioral defense mechanisms [3,4]. Furthermore, experimentally induced disgust has been shown to influence social and mating-related preferences, suggesting a broader role of disgust in human adaptive behavior [9].
Perceived Vulnerability to Disease (PVD) represents another important component of the behavioral immune system and reflects individual differences in beliefs and concerns regarding susceptibility to infectious diseases [10]. Together with disgust sensitivity, PVD contributes to behavioral strategies aimed at minimizing pathogen exposure and maintaining health [7]. Quantitative synthesis of this literature has become available only recently: a meta-analysis of 74 sources reported that perceived infectability shows only small associations with disgust sensitivity and non-significant associations with outgroup perceptions, whereas germ aversion displays a different pattern, indicating that the components of the BIS should be modeled as distinct rather than interchangeable constructs [11]. To the best of our knowledge, however, no quantitative synthesis published to date has specifically addressed the hormonal modulation of behavioral immune responses, which remains documented only by a small number of primary studies.
In addition to general disgust sensitivity, body odor processing may represent a particularly relevant domain in this context [12]. Olfactory cues contribute to social communication, mate selection, pathogen detection, and emotional processing. Sensitivity to body odors has been associated with disease-avoidance tendencies, moral evaluations, and aspects of sexual functioning [13,14,15,16]. Recent evidence further highlights the broader role of olfaction in human sexuality and social behavior [12].
Gender-affirming hormone therapy (GAHT) provides a unique human model for investigating the influence of sex steroids on psychological functioning. Unlike naturally occurring hormonal fluctuations, GAHT induces substantial and sustained modifications in circulating T and E2 concentrations, allowing the prospective evaluation of endocrine-related psychological changes within the same individuals [1,2]. Although previous research has examined the effects of GAHT on mood, quality of life, body image, and social functioning, little is known about its potential influence on disgust-related processes and other components of the BIS.
To date, no longitudinal study has systematically examined changes in pathogen disgust, sexual disgust, moral disgust, body odor disgust, and perceived vulnerability to disease during the early phases of GAHT. The present prospective study aimed to investigate whether endocrine changes occurring during the first four months of masculinizing or feminizing hormone therapy are associated with modifications in these behavioral and affective domains. We hypothesized that GAHT-related hormonal changes would be accompanied by selective alterations in specific dimensions of disgust sensitivity and PVD and that the magnitude of endocrine changes would be associated with the extent of psychological change observed over time.

2. Materials and Methods

2.1. Study Design and Participants

This prospective observational study was conducted at the Gender Identity Outpatient Clinic of the Azienda Ospedaliero-Universitaria Renato Dulbecco, Catanzaro, Italy. Participants were consecutively recruited in February 2026 among individuals seeking initiation of GAHT.
Eligibility criteria included age ≥ 18 years; a diagnosis of gender incongruence according to contemporary clinical guidelines and to the International Classification of Diseases, 11th Revision (ICD-11) [17,18]; and eligibility for GAHT following multidisciplinary assessment. Exclusion criteria included severe psychiatric conditions impairing participation, major neurological disorders, active substance abuse, and inability to complete self-administered questionnaires.
A total of 25 transgender individuals were enrolled, including 12 transmasculine (female-to-male; FtM) and 13 transfeminine (male-to-female; MtF) participants. All participants underwent assessment before initiating hormone therapy (baseline, T0) and after four months of treatment (follow-up, T1).
The study was conducted in accordance with the Declaration of Helsinki and was approved by the Calabria Region Ethics Committee (Protocol No. 25/2026, date of approval 20 January 2026). Written informed consent was obtained from all participants before enrollment. The four-month interval corresponds to the first scheduled endocrinological re-evaluation of our institutional protocol, at which serum hormone concentrations are routinely reassessed and treatment is titrated; assessment at this time point therefore did not require any additional visit or procedure beyond routine clinical care. No a priori sample size calculation was performed: the study included all consecutive individuals judged eligible for GAHT during the recruitment window who completed both assessments, so the sample size was determined by clinical throughput rather than by statistical planning.
The study was reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [19].

2.2. GAHT and Endocrine Assessment

Participants received GAHT according to Endocrine Society recommendations and local clinical practice [1,2]. Transmasculine individuals received masculinizing hormone therapy consisting of either transdermal testosterone gel or intramuscular testosterone undecanoate depending upon each individual patient’s compliance with respect to menstrual cycle withdrawal. Treatment was titrated to maintain serum testosterone concentrations within the physiological male reference range, to ensure adequate suppression of the hypothalamic–pituitary–ovarian axis, and to preserve hematocrit levels within normal limits.
Transfeminine individuals received feminizing hormone therapy, consisting of standardized androgen suppression with the gonadotropin-releasing hormone (GnRH) analogue triptorelin acetate (3.75 mg monthly) to suppress the hypothalamic–pituitary–testicular axis, combined with estrogen therapy administered either as transdermal estradiol (50 mcg weekly) or oral estradiol valerate (10 mg daily) depending upon each individual patient’s compliance with respect to the preference of route of administration in order to achieve desired feminization while maintaining safety parameters.
Blood samples were collected during scheduled endocrinological visits in the morning after overnight fasting. Serum T and E2 concentrations were measured at baseline (T0) and after four months of treatment (T1) as part of routine clinical monitoring.
Hormonal assays were performed at the central laboratory of the Renato Dulbecco University Hospital using an automated chemiluminescence immunoassay platform (ADVIA Centaur XP, Siemens Healthineers, Erlangen, Germany), according to manufacturer specifications and standard laboratory procedures.
For each participant, endocrine change scores (Δ) were calculated as the difference between follow-up and baseline values (T1 − T0).

2.3. Psychometric Assessment

All instruments were administered in their published Italian versions; no ad hoc translation or back-translation was performed by the authors, and no item was modified so that the cultural adaptation of each instrument corresponds to that documented in the validation studies cited below. Questionnaires were self-administered in a quiet clinical setting immediately before the scheduled endocrinological visit, in the same order and under the same conditions at T0 and T1. Internal consistency was computed in the present sample at both time points and is reported for each scale.

2.3.1. Three Domains of Disgust Scale (TDDS)

Disgust sensitivity was assessed using the TDDS [8], a 21-item self-report instrument designed to measure individual differences across three functional domains of disgust:
  • Pathogen disgust;
  • Sexual disgust;
  • Moral disgust.
Items are rated on a 7-point Likert scale ranging from 0 (“not disgusting at all”) to 6 (“extremely disgusting”), with higher scores indicating greater disgust sensitivity. Each domain is measured by seven items, so subscale scores range from 0 to 42. The Italian version administered in the present study is the one whose psychometric properties were examined in the study by Poli, Melli, and Radomsky, in which exploratory and confirmatory factor analyses in a large Italian community sample (N = 1077) confirmed the three-factor structure and supported the internal consistency and construct validity of the Italian adaptation [20]. In the present sample, Cronbach’s α was 0.733 for pathogen, 0.700 for sexual disgust, and 0.900 for moral disgust at T0 and 0.929, 0.700, and 0.917, respectively, at T1. Global score α was 0.875 at T0 and 0.917 at T1.
Following the original conceptualization of the TDDS, in the present study, pathogen, sexual, and moral disgust scores were analyzed separately, rather than as a single composite measure, as they reflect distinct evolutionary and psychological functions and may respond differently to biological influences [8]. The Italian version of the TDDS has demonstrated a solid tridimensional factorial structure, good internal consistency, and construct validity in Italian populations [20].

2.3.2. Body Odor Disgust Scale (BODS)

Sensitivity to body odor cues was assessed using the BODS [12].
The BODS evaluates emotional reactions to a range of body odor-related situations and provides an index of individual differences in body odor disgust sensitivity. Higher scores indicate greater disgust responses toward body odor stimuli.
The scale has demonstrated good psychometric properties and has been associated with disease-avoidance tendencies, moral judgments, and social evaluations [12,13]. The Italian adaptation of the BODS has been recently validated, confirming its bifactor structure and demonstrating excellent structural, construct, and criterion validity, as well as measurement invariance across genders [21]. The instrument comprises 12 items presenting six body odor-related scenarios, each referred both to an internal source (the participant’s own body) and to an external source (another person’s body), rated on a five-point scale ranging from 1 (“not disgusting at all”) to 5 (“extremely disgusting”), yielding a total score ranging from 12 to 60, with higher scores indicating greater body odor disgust sensitivity. The Italian validation was conducted in two samples representative of the Italian population for sex and age (N = 1050 and N = 402) [21]. In the present sample, Cronbach’s α was 0.939 at T0 and 0.931 at T1.

2.3.3. PVD Scale

PVD was assessed using the PVD Scale [10].
The instrument measures beliefs and concerns regarding susceptibility to infectious diseases and is widely used as an indicator of BIS activation.
Higher scores indicate greater perceived vulnerability to illness and stronger concerns regarding pathogen exposure. The Italian version of the PVD questionnaire (I-PVDQ) has been recently validated, confirming the original two-factor structure (Perceived Infectability and Germ Aversion) and showing strict measurement invariance across genders and good psychometric properties [22]. The scale comprises 15 items rated on a seven-point scale and distributed across the Perceived Infectability and Germ Aversion subscales; reverse-keyed items were recoded before scoring, and total scores range from 15 to 105. The Italian validation study, conducted in 509 participants, supported the two-factor structure of the questionnaire and its measurement invariance across gender [22]. In the present study, the total PVD score was used as the primary outcome to limit the number of exploratory comparisons and because the small sample was not adequately powered to examine the Perceived Infectability and Germ Aversion subscales separately. This analytical choice should not be interpreted as implying that the two PVD dimensions are conceptually interchangeable. Cronbach’s α for the total score was 0.700 at T0 and 0.701 at T1.

2.4. Statistical Analysis

Statistical analyses were performed using IBM SPSS Statistics version 23.0.
Continuous variables are presented as mean ± standard deviation (SD). Given the limited sample size and the non-normal distribution of several variables, non-parametric procedures were employed.
All analyses were conducted separately for FtM and MtF participants.
Changes between T0 and T1 were evaluated using Wilcoxon signed-rank tests for paired samples.
For each participant, change scores (Δ = T1 − T0) were calculated for T, E2, BODS, PVD, pathogen disgust, sexual disgust, and moral disgust.
Associations between endocrine and psychometric changes were examined using Spearman rank-order correlations, calculated separately for the FtM and MtF groups. The analyses were exploratory and hypothesis-generating. Ten Wilcoxon signed-rank tests (five psychometric outcomes in each of the two groups) and twenty Spearman rank-order correlations (five psychometric change scores examined in relation to two hormonal change scores in each group) were performed. Unadjusted p values were retained for the primary exploratory analyses to reduce the risk of Type II error in this small sample. However, because the number of tests increases the risk of Type I error, these results were interpreted as preliminary signals rather than confirmatory findings. As a sensitivity analysis, the Benjamini–Hochberg false discovery rate (FDR) procedure was applied separately to each of four families of tests: the five within-group comparisons in FtM participants, the five within-group comparisons in MtF participants, the ten correlations in FtM participants, and the ten correlations in MtF participants. The conclusions of the FDR sensitivity analysis are reported in Section 3. No statistical comparison was performed between FtM and MtF participants. The two groups were analyzed separately throughout; no between-group inference was drawn, and any apparent difference between their results was considered descriptive only. Internal consistency was assessed using Cronbach’s alpha (α); values ≥ 0.70 were considered acceptable.
For the primary unadjusted analyses, two-sided nominal statistical significance was set at p < 0.05.

3. Results

3.1. Participant Characteristics and Endocrine Changes

A total of 25 transgender participants completed both study assessments, including 12 FtM and 13 MtF individuals.
Baseline demographic and endocrine characteristics are reported in Table 1. The mean age was 20.8 ± 1.9 years in the FtM group and 23.1 ± 10.2 years in the MtF group.
Table 1. Demographic and endocrine characteristics of the study population. Variables are presented as means ± standard deviations.
As expected, GAHT induced substantial endocrine changes in both groups. In FtM participants, serum T concentrations increased markedly from 43.4 ± 20.5 ng/dL at baseline to 681.3 ± 380.2 ng/dL after four months of treatment. E2 concentrations showed only modest variation during follow-up.
In MtF participants, T concentrations decreased substantially from 528.1 ± 199.7 ng/dL to 25.8 ± 10.6 ng/dL, while E2 concentrations increased from 35.8 ± 16.9 pg/mL to 96.7 ± 59.0 pg/mL.

3.2. Changes in Disgust Sensitivity, Body Odor Disgust, and PVD

Changes in psychometric measures are reported in Table 2.
Table 2. Changes in psychometric measures during GAHT. Variables are presented as means ± standard deviations.
Among FtM participants, PVD increased significantly during follow-up (55.33 ± 8.04 at T0 vs. 58.83 ± 8.82 at T1; p = 0.039). No significant changes were observed in body odor disgust (BODS; p = 0.078), pathogen disgust (p = 0.583), sexual disgust (p = 0.125), or moral disgust (p = 0.064).
Among MtF participants, pathogen disgust increased significantly after four months of treatment (17.69 ± 6.75 at T0 vs. 24.23 ± 5.76 at T1; p = 0.015). No significant changes were observed in body odor disgust (p = 0.328), PVD (p = 0.532), sexual disgust (p = 0.722), or moral disgust (p = 0.481).
After Benjamini–Hochberg adjustment within each family of five within-group comparisons, none of the changes observed in FtM participants remained significant (all adjusted p ≥ 0.13), and the increase in pathogen disgust in MtF participants approached but did not reach the adjusted threshold (adjusted p = 0.075). The uncorrected results are presented in full for transparency and for future meta-analytic use, but they should be read as exploratory signals requiring independent replication rather than as established effects.

3.3. Associations Between Endocrine Changes and Psychometric Changes in FtM Participants

Correlations between hormonal changes and psychometric changes in FtM participants are summarized in Table 3.
Table 3. Correlations between hormonal changes and psychometric changes in FtM participants.
Greater increases in T were significantly associated with greater reductions in moral disgust (ρ = −0.671, p < 0.05). No significant associations were observed between T changes and changes in body odor disgust, PVD, pathogen disgust, or sexual disgust. Greater increases in E2 were significantly associated with greater reductions in body odor disgust (ρ = −0.612, p < 0.05), whereas no other association between E2 changes and psychometric changes reached significance. Neither of these two associations survived Benjamini–Hochberg adjustment.

3.4. Associations Between Endocrine Changes and Psychometric Changes in MtF Participants

Correlations between hormonal changes and psychometric changes in MtF participants are reported in Table 4.
Table 4. Correlations between hormonal changes and psychometric changes in MtF participants.
Greater increases in E2 were significantly associated with greater increases in moral disgust (ρ = 0.587, p < 0.05) and lower PVD (ρ = −0.748, p < 0.01). No significant associations were observed between E2 changes and body odor disgust, pathogen disgust, or sexual disgust.
Changes in T were positively associated with changes in sexual disgust (ρ = 0.570, p < 0.05). No significant associations emerged between T changes and body odor disgust, perceived vulnerability to disease, pathogen disgust, or moral disgust. None of the associations observed in this group survived Benjamini–Hochberg adjustment.

4. Discussion

The present prospective study examined longitudinal changes in disgust sensitivity, body odor disgust, and PVD during the first four months of GAHT in transgender individuals. To our knowledge, this is among the first studies to investigate the relationship between endocrine changes induced by GAHT and psychological dimensions related to the BIS, integrating hormonal and psychometric assessments prospectively collected before and after treatment initiation.
Recent high-profile literature has further emphasized the broad role of the BIS in modulating social interactions, highlighting how this system might function as a ‘smoke detector’ that generates social prejudice and avoidance towards perceived atypicality [23].
Overall, the findings are compatible with selective rather than global changes in disgust-related processes; because none of them survived correction for multiple testing, they are described below as candidate patterns rather than as demonstrated effects. While relatively few psychometric measures changed significantly at the group level (i.e., PVD in transmasculine individuals and pathogen disgust in transfeminine individuals), several significant associations emerged between endocrine changes and specific dimensions of disgust sensitivity. Consistent with the multidimensional framework proposed by Tybur et al. [8], changes were not uniformly distributed across the different domains of disgust. Pathogen, sexual, and moral disgust represent partially independent components that may respond differently to biological and psychosocial influences. The present findings support this perspective, as significant associations were observed only for selected domains and differed between transmasculine and transfeminine participants.
Among transmasculine participants, greater increases in T were associated with greater reductions in moral disgust. Moral disgust is increasingly recognized not only as a mechanism involved in social norm enforcement but also as a broader socio-evaluative process contributing to judgments of social behavior and norm violations [8]. This association did not survive correction for multiple testing, was estimated in twelve participants, and is therefore reported only as a candidate hypothesis. Should it be replicated in an adequately powered sample, it would be compatible with experimental and neuroendocrine evidence suggesting that T influences social approach behaviors, threat appraisal, and responses to socially relevant stimuli; the present data, however, provide no basis for asserting such a mechanism, and alternative explanations, including chance, regression to the mean, and psychosocial changes concurrent with treatment initiation, cannot be excluded. An additional finding in the FtM group was the significant increase in PVD. Importantly, changes in PVD were not significantly associated with changes in T or E2 concentrations. Consequently, the mechanisms underlying this finding remain uncertain. PVD reflects cognitive appraisals of susceptibility to illness rather than immediate affective responses to contamination-related stimuli [10], suggesting that cognitive perceptions of vulnerability and emotional disease-avoidance responses may represent partially independent components of the BIS. It is therefore possible that factors other than endocrine variation contributed to the observed increase in PVD during the early stages of masculinizing hormone therapy.
Among transfeminine participants, pathogen disgust increased significantly following four months of treatment. However, changes in pathogen disgust were not significantly correlated with changes in E2 concentrations. Consequently, the biological mechanisms underlying this finding remain unclear. The observed increase may reflect a combination of endocrine, psychosocial, and contextual factors occurring during the early phases of feminizing hormone therapy. Previous studies have reported sex differences in pathogen disgust and disease-avoidance tendencies [8,9], but further longitudinal research will be required to determine whether the changes observed in the present study are directly attributable to hormonal influences.
Correlation analyses further demonstrated that greater increases in E2 were associated with greater increases in moral disgust. Interestingly, moral disgust emerged as the dimension most consistently associated with endocrine changes across both FtM and MtF participants. Although no significant group-level changes in moral disgust were observed, the correlations suggest that this domain may be particularly sensitive to individual hormonal variation. These findings support the hypothesis that sex steroids may influence socio-affective processes related to social evaluation and norm-based judgments, although future studies will be required to clarify the neurobiological mechanisms involved.
The strongest association observed in the study was the negative correlation between changes in E2 and changes in PVD. Participants showing larger increases in E2 reported lower perceived vulnerability at follow-up. This finding suggests that endocrine changes may influence cognitive representations of bodily vulnerability differently from emotional disgust responses. Given the physical and psychological changes associated with GAHT, improved body congruence, greater self-confidence, and enhanced psychological well-being may also contribute to reduced perceptions of vulnerability. Nevertheless, these interpretations remain speculative and require direct investigation in future studies. This association did not survive correction for multiple testing and must not be read as evidence of an effect. Contrary to our expectations, body odor disgust did not significantly change in either group. A single significant association emerged between the increase in E2 and the reduction in body odor disgust in transmasculine participants; it did not survive correction for multiple testing and is therefore not discussed further as an effect. Body odors represent biologically relevant social and health-related cues, and previous studies have shown that body odor disgust is associated with pathogen-avoidance tendencies, moral judgments, and social evaluations [13,14]. The relative stability of BODS scores over the study period may suggest that body odor disgust is less responsive to short-term endocrine changes than other disgust-related dimensions. This interpretation is consistent with evidence linking olfactory processing to relatively stable aspects of sociosexual functioning and interpersonal relationships [12,15,16].
Several limitations should be considered when interpreting these findings. First, the sample was small, and no a priori sample size calculation was performed. With 12 transmasculine and 13 transfeminine participants, a Spearman correlation reaches the conventional two-tailed threshold of p < 0.05 only when its absolute value exceeds approximately 0.58 and 0.55, respectively, and approximately 80% power would have required absolute values of approximately 0.73 and 0.70. Associations of small or moderate magnitude could therefore not have been detected, so the absence of a significant association cannot be read as evidence of absence; conversely, the associations that did reach significance are by construction large ones, and effect sizes estimated in samples of this size are systematically inflated relative to their population values, so that the coefficients reported here should be regarded as upper bounds rather than as point estimates. Second, the study did not include a control group, and three comparator designs were considered. A cisgender control group would have controlled for the passage of time and for repeated administration of the questionnaires, but not for the exposure of interest, since no comparable sustained modification of circulating sex steroid concentrations occurs spontaneously. A waiting-list group of transgender individuals assessed twice before treatment would have been the methodologically preferable comparator, as it would have controlled simultaneously for time, repeated testing, and the psychosocial context of gender transition; this design was not feasible at our center, because all individuals judged eligible after multidisciplinary assessment begin GAHT without a deferral period, and deliberately postponing treatment for research purposes would not have been ethically acceptable. A direct statistical comparison between transmasculine and transfeminine participants was deliberately not performed because the two groups differ simultaneously in sex assigned at birth, treatment regimen, and direction of hormonal change, so any difference would be uninterpretable. The within-subject prospective design, in which each participant serves as their own control, was therefore adopted as the only feasible option, and its consequences must be stated plainly: the present data cannot distinguish change attributable to hormone therapy from change attributable to the passage of time, to repeated assessment and familiarity with the instruments, to participant expectancy, to regression to the mean, or to the broader psychosocial process of gender transition, which includes social affirmation, changes in interpersonal relationships, and reduced gender-related distress. Third, the four-month follow-up captures only the initial phase of adaptation, and this limitation is not symmetrical across the two groups: whereas circulating testosterone in transmasculine individuals typically approaches the target range within the first months of treatment, feminization in transfeminine individuals proceeds over a considerably longer period, so the transfeminine data in particular describe an early and non-stationary phase; psychological adaptation, moreover, is likely to follow a slower time course than the endocrine one. Finally, the observational design precludes causal inference, and no correction for multiple comparisons was applied in the primary analysis; as reported in Section 3, the FDR sensitivity analysis indicates that the present findings should be regarded as hypothesis-generating rather than confirmatory. Despite these limitations, the present findings may inform the design and powering of adequately controlled confirmatory studies, rather than supporting any claim that sex steroids selectively influence specific components of the BIS. The most consistent associations involved moral disgust and perceived vulnerability to disease, highlighting the potential relevance of sex steroids in the modulation of socio-affective and disease-related cognitive processes. By integrating endocrinological and psychological measures, this study contributes to the growing literature examining the broader correlates of GAHT. Future multicenter longitudinal studies with larger samples, longer follow-up periods, and more comprehensive assessments of endocrine, psychological, and sensory functioning will be necessary to clarify the mechanisms underlying these associations and their potential clinical relevance.

5. Conclusions

This prospective study describes, in a small exploratory cohort, the co-occurrence of endocrine and behavioral immune system changes during the first four months of GAHT. Associations were observed between changes in sex steroids and changes in specific domains of disgust sensitivity and in perceived vulnerability to disease: in transmasculine participants, increases in T co-occurred with reductions in moral disgust, whereas in transfeminine participants, increases in E2 co-occurred with higher moral disgust and lower PVD; pathogen disgust also increased at the group level among transfeminine participants. However, none of these findings survived correction for multiple testing, and the observational design does not permit any causal inference regarding the effects of hormone therapy. These data are reported because the direction and magnitude of the associations described may inform the design of adequately powered and controlled confirmatory studies. Larger longitudinal studies with extended follow-up periods are needed to establish whether any of these associations are genuine.

Author Contributions

Conceptualization, A.A.; methodology, A.A. and E.D.; formal analysis, E.D. and P.S.; investigation, M.C.Z., A.R. and A.G.; data curation, A.R. and A.G.; writing—original draft preparation, M.C.Z.; writing—review and editing, E.A.G., M.L., G.S. and A.A.; supervision, A.A. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Calabria Region Ethics Committee (protocol code: 25/2026; date of approval: 20 January 2026).

Data Availability Statement

The data presented in this study are available upon request from the corresponding author due to privacy reasons.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
BISBehavioral Immune System
BODSBody Odor Disgust Scale
E2Estradiol
FtMFemale-to-Male (transmasculine)
GAHTGender-Affirming Hormone Therapy
GnRHGonadotropin-Releasing Hormone
ICD-11International Classification of Diseases, 11th Revision
MtFMale-to-Female (transfeminine)
PVDPerceived Vulnerability to Disease
SDStandard Deviation
SPSSStatistical Package for the Social Sciences
STROBEStrengthening the Reporting of Observational Studies in Epidemiology
TTestosterone
T0Baseline Assessment
T1Four-Month Follow-Up Assessment
TDDSThree Domains of Disgust Scale

References

  1. Hembree, W.C.; Cohen-Kettenis, P.T.; Gooren, L.; Hannema, S.E.; Meyer, W.J.; Murad, M.H.; Rosenthal, S.M.; Safer, J.D.; Tangpricha, V.; T’Sjoen, G.G. Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2017, 102, 3869–3903. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  2. D’hoore, L.; T’Sjoen, G. Gender-affirming hormone therapy: An updated literature review with an eye on the future. J. Intern. Med. 2022, 291, 574–592. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  3. Fleischman, D.S.; Fessler, D.M.T. Progesterone’s effects on the psychology of disease avoidance: Support for the compensatory behavioral prophylaxis hypothesis. Horm. Behav. 2011, 59, 271–275. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  4. Kaňková, Š.; Dlouhá, D.; Ullmann, J.; Velíková, M.; Včelák, J.; Hill, M. Association between disgust sensitivity during pregnancy and endogenous steroids: A longitudinal study. Int. J. Mol. Sci. 2024, 25, 6857. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  5. Curtis, V.; Biran, A. Dirt, disgust, and disease: Is hygiene in our genes? Perspect. Biol. Med. 2001, 44, 17–31. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  6. Oaten, M.; Stevenson, R.J.; Case, T.I. Disgust as a disease-avoidance mechanism. Psychol. Bull. 2009, 135, 303–321. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  7. Schaller, M.; Park, J.H. The behavioral immune system (and why it matters). Curr. Dir. Psychol. Sci. 2011, 20, 99–103. [Google Scholar] [CrossRef] [Scilit]
  8. Tybur, J.M.; Lieberman, D.; Griskevicius, V. Microbes, mating, and morality: Individual differences in three functional domains of disgust. J. Pers. Soc. Psychol. 2009, 97, 103–122. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  9. Al-Shawaf, L.; Lewis, D.M.G.; Ghossainy, M.E.; Buss, D.M. Experimentally inducing disgust reduces desire for short-term mating. Evol. Psychol. Sci. 2019, 5, 267–275. [Google Scholar] [CrossRef] [Scilit]
  10. Duncan, L.A.; Schaller, M.; Park, J.H. Perceived vulnerability to disease: Development and validation of a 15-item self-report instrument. Pers. Individ. Dif. 2009, 47, 541–546. [Google Scholar] [CrossRef] [Scilit]
  11. Howard, M.C.; Davis, M.M.; Serviss, E. A meta-analysis of perceived infectability, germ aversion, disgust and outgroup perceptions: Evaluating research on the behavioural immune system. Br. J. Psychol. 2026. advance online publication. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  12. Leuzzi, M.; Seminara, G.; Zagari, M.C.; Bossio, S.; Aversa, A. The multifaceted role of olfaction in human sexuality: A narrative review. Sexes 2026, 7, 28. [Google Scholar] [CrossRef] [Scilit]
  13. Liuzza, M.T.; Lindholm, T.; Hawley, C.; Sendén, M.G.; Ekström, I.; Olsson, M.J.; Larsson, M.; Olofsson, J.K. The Body Odor Disgust Scale (BODS): Development and validation of a novel olfactory disgust assessment. Chem. Senses 2017, 42, 499–508. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  14. Liuzza, M.T.; Olofsson, J.K.; Cancino-Montecinos, S.; Lindholm, T. Body odor disgust sensitivity predicts moral harshness toward moral violations of purity. Front. Psychol. 2019, 10, 458. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  15. Blomkvist, A.; Izzo, G.; Vaccaro, M.G.; La Vignera, S.; Brunetti, A.; Aversa, A.; Liuzza, M.T. The scent of monogamy: Self-reported olfactory function predicts sexual well-being and infidelity in an Italian population. Arch. Sex. Behav. 2022, 51, 2879–2889. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  16. Iuliano, S.; Zagari, M.C.; Frasca Polara, G.; Rotella, G.; La Vignera, S.; Greco, E.A.; Liuzza, M.T.; Aversa, A. Global olfactory function correlates with global sexual functioning in men and women. Minerva Med. 2023, 114, 785–794. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  17. World Professional Association for Transgender Health. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int. J. Transgend. Health 2022, 23, S1–S259. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  18. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 11th Revision (ICD-11); World Health Organization: Geneva, Switzerland, 2022. [Google Scholar]
  19. Von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gøtzsche, P.C.; Vandenbroucke, J.P.; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. BMJ 2007, 335, 806–808. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  20. Poli, A.; Melli, G.; Radomsky, A.S. Different disgust domains specifically relate to mental and contact contamination fear in obsessive-compulsive disorder: Evidence from a path analytic model in an Italian clinical sample. Behav. Ther. 2019, 50, 380–394. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  21. Liuzza, M.T.; Zakrzewska, M.Z.; Olofsson, J.K. Italian validation of the body odor disgust scale. Front. Behav. Neurosci. 2024, 18, 1389905. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  22. Chiesi, F.; Marunic, G.; Tagliaferro, C.; Lau, C. The psychometric properties and gender invariance of the Italian version of the Perceived Vulnerability to Disease Questionnaire (I-PVDQ) during the COVID-19 pandemic. BMC Psychol. 2022, 10, 321. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  23. Van Leeuwen, F.; Jaeger, B.; Tybur, J.M. A behavioural immune system perspective on disgust and social prejudice. Nat. Rev. Psychol. 2023, 2, 676–687. [Google Scholar] [CrossRef] [Scilit]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.